Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase II trial of BCX-4208 with or without allopurinol initiated in gout

June 2, 2010

Wyeth Europa notifies EMA of withdrawal of MAA for Brilence

June 1, 2010

FDA committee recommends approval of tesamorelin

May 31, 2010

Prolia obtains marketing authorization in E.U.

May 31, 2010

NICE issues recommendation for somatropin products, including Omnitrope

May 31, 2010

Galderma claims new melanocortin MC4 receptor antagonists

May 31, 2010

Merck & Co. presents new somatostatin receptor sst3 antagonists

May 28, 2010

FDA approves Lumizyme for late-onset Pompe's disease

May 27, 2010

Cytochroma reports phase I/II data on CTAP-101 in CKD-associated hyperparathyroidism

May 27, 2010

ONO-5334 shows promise in postmenopausal osteoporosis

May 26, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...